Tower Research Capital LLC (Trc) Arcutis Biotherapeutics, Inc. Transaction History
Tower Research Capital LLC (Trc)
- $5.8 Billion
- Q2 2024
A detailed history of Tower Research Capital LLC (Trc) transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 18,920 shares of ARQT stock, worth $177,091. This represents 0.0% of its overall portfolio holdings.
Number of Shares
18,920
Previous 2,388
692.29%
Holding current value
$177,091
Previous $23,000
660.87%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding ARQT
# of Institutions
193Shares Held
127MCall Options Held
5.43MPut Options Held
257K-
Jennison Associates LLC11.6MShares$108 Million0.07% of portfolio
-
Suvretta Capital Management, LLC New York, NY10MShares$93.6 Million3.89% of portfolio
-
Rubric Capital Management LP New York, NY9.82MShares$91.9 Million2.7% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA8.79MShares$82.2 Million4.82% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$80.7 Million0.0% of portfolio
About Arcutis Biotherapeutics, Inc.
- Ticker ARQT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,187,500
- Market Cap $563M
- Description
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...